TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02229149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
Description: physician's choice of chemotherapy:~* Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~* Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~* Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~* Docetaxel 75 mg/m2 IV every 3 weeks; OR~* Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
Description: physician's choice of chemotherapy:~* Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~* Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~* Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~* Docetaxel 75 mg/m2 IV every 3 weeks; OR~* Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.
Study: NCT01334125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000 mg once daily by mouth for 9 months
Study: NCT04541693

Intervention type: DEVICE
Group type: OTHER
Intervention: Stem revision
Description: Only the stem requires revision
Study: NCT03531827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: enzalutamide is an androgen receptor (AR) antagonist that is standard care therapy for metastatic prostate cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX101
Description: CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX101
Description: CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)
Study: NCT02216981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Study: NCT01334125

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules once daily by mouth for 9 months
Study: NCT04283045

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASPER
Description: JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the TA.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASPER Plus+
Description: JASPER Plus+ refers to direct instruction of social communication targets of pointing to share, showing gesures, and give to share gestures, and play targets at the child's target play level.~JASPER Plus+ will occur at a table top with repeated trials of instruction until the child can produce the desired behavior on their own.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASPER Plus+
Description: JASPER Plus+ refers to direct instruction of social communication targets of pointing to share, showing gesures, and give to share gestures, and play targets at the child's target play level.~JASPER Plus+ will occur at a table top with repeated trials of instruction until the child can produce the desired behavior on their own.
Study: NCT04028843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Beginnings
Description: The program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the smartphone application, personalized feedback from counselors and, evidence-based behavioral intervention delivered throughout pregnancy.
Study: NCT02006303

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Green light PVP
Description: The green light laser has a wavelength of 532 nm which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. The procedure uses the technology of high-powered laser light combined with fiber optics to vaporize the overgrowth of prostate cells quickly and accurately. As the surgeon directs the laser at the prostate, the intense pulses of light emitted from the fiber are absorbed by the blood. Within moments, the temperature of the blood becomes so great it causes the nearby cells to vaporize. Once the procedure is completed, patients have immediate post-operative symptom relief and dramatic improvements in symptoms, urinary flow rates, and bladder emptying.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostatic artery embolization
Description: Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
Study: NCT02907697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Steps-Drug Use

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Education
Study: NCT00894751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: dexmedetomidine general anesthesia for MRI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol general anesthesia for MRI
Study: NCT02451423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg Given IV
Study: NCT01593735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2748
Description: MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2748
Description: MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2748
Description: MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2748
Description: MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2748
Description: MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2748
Description: MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2748
Description: MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2748
Description: MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment
Study: NCT03087123

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: P-Mobile App
Description: The behavioral strategies are based on Social Cognitive Theory. The following topics will be covered: self-monitoring, goal setting, stimulus control, making time for exercise, exercising in- and outdoors, problem-solving, reinforcing PA, reducing sedentary behaviors, relapse prevention, parental modeling, lifestyle exercise, self-efficacy, self-management, parental PA modeling, parental co-participation, and establishing PA rules. Parents will be provided with adapted step goals (based on principles of shaping). Text messages will be designed to prompt PA, remind parents of concepts from the lessons, and motivate behavioral change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: P-Mobile App
Description: The behavioral strategies are based on Social Cognitive Theory. The following topics will be covered: self-monitoring, goal setting, stimulus control, making time for exercise, exercising in- and outdoors, problem-solving, reinforcing PA, reducing sedentary behaviors, relapse prevention, parental modeling, lifestyle exercise, self-efficacy, self-management, parental PA modeling, parental co-participation, and establishing PA rules. Parents will be provided with adapted step goals (based on principles of shaping). Text messages will be designed to prompt PA, remind parents of concepts from the lessons, and motivate behavioral change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: P-Mobile App
Description: The behavioral strategies are based on Social Cognitive Theory. The following topics will be covered: self-monitoring, goal setting, stimulus control, making time for exercise, exercising in- and outdoors, problem-solving, reinforcing PA, reducing sedentary behaviors, relapse prevention, parental modeling, lifestyle exercise, self-efficacy, self-management, parental PA modeling, parental co-participation, and establishing PA rules. Parents will be provided with adapted step goals (based on principles of shaping). Text messages will be designed to prompt PA, remind parents of concepts from the lessons, and motivate behavioral change.
Study: NCT02440529

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Discussion
Study: NCT01593735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2748
Description: MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2748
Description: MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment
Study: NCT02440529

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal Group
Description: Detailed Discussion
Study: NCT01593735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, once daily for 7 days
Study: NCT01140659

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Video-assisted sympathectomy
Description: All participants were randomized into two groups of 20 patients (G3 and G4) and underwent video-assisted sympathectomy, being followed for 12 months. During this period, the subjects completed a questionnaire about quality of life and carried out the measurements of sweat by VapoMeter.
Study: NCT00510796

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview regarding perception of pain and the benefits and barriers to the combined screening.
Study: NCT04253197

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: Pregnant women in 3rd trimester with anterior placenta previa and lower cesarean section scar. Ultrasound was done and according to parameters of the morbidly adherent placenta, a staging system was conducted.
Study: NCT00649129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride ER Tablets 10 mg
Description: 2x10mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ditropan XL® Tablets 10 mg
Description: 2x10mg, single dose fasting
Study: NCT02541539

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus casei Zhang
Description: This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
Study: NCT01874327

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baby JASPER
Description: Intervention focuses on core deficits of joint attention, play, engagement, and regulation embedded within AEPS curriculum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Baby Classroom
Description: Assessment, Education and Programming System (AEPS) for Infants and Children curriculum focused on early developmental milestones in fine and gross motor, cognitive, adaptive and social areas
Study: NCT04178200

Intervention type: DRUG
Intervention: Lidocaine 2% Injectable Solution 0.75 ml
Description: 0.75 ml of Lidocaine will be added to the anesthetic solution.

Intervention type: DRUG
Intervention: Bupivacaine Hcl 0.5% Inj 0.75 ml
Description: 0.75 ml of Bupivacaine will be added to the anesthetic solution.

Intervention type: DRUG
Intervention: Lidocaine 2% Injectable Solution 1.5 ml
Description: 1.5 ml of Lidocaine will be added to the anesthetic solution.

Intervention type: DRUG
Intervention: Bupivacaine Hcl 0.5% Inj 1.5 ml
Description: 1.5 ml of Bupivacaine will be added to the anesthetic solution.
Study: NCT01579019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1500 mg po bid, 24 or 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1500 mg po bid, 24 or 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO5024048
Description: 1000 mg po bid, 24 or 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO5024048
Description: 1000 mg po bid, 24 or 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: 100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: 100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc qw, 24 or 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc qw, 24 or 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc qw, 24 or 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc qw, 24 or 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg po daily, 24 or 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg po daily, 24 or 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg po daily, 24 or 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg po daily, 24 or 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: 100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
Study: NCT01114620

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arepanrix™
Description: Intramuscular administration, one dose
Study: NCT03590743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Active anticoagulation with apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily to complete a total of 3 months treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: apixaban matching placebo 2 tablets twice daily for 7 days followed by one tablet twice daily to complete a total of 3 months.
Study: NCT02313558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dentifrice Containing Ilex Rotunda Thunb
Description: Use the dentifrice to brush teeth twice a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control dentifrice
Description: Use the dentifrice to brush teeth twice a day for 12 weeks
Study: NCT03505996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS1001
Description: Monoclonal antibody
Study: NCT01251068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: near infrared spectroscopy: invos 5100
Description: duration:six hours
Study: NCT04408001

Intervention type: OTHER
Intervention: Clinical interview
Description: At each study visit, participants will be questioned by a physician about their persistent symptoms or the existence of intercurrent infections that may resemble COVID-19.

Intervention type: OTHER
Intervention: Clinical interview
Description: At each study visit, participants will be questioned by a physician about their persistent symptoms or the existence of intercurrent infections that may resemble COVID-19.

Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: At each study visit,~* 1 EDTA tube for complete blood count~* 3 dry tubes with gel for serology, serum neutralisation test and serum library~* 1 cell preparation tube for the separation of immune cells within the circulating blood will be collected.

Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: At each study visit,~* 1 EDTA tube for complete blood count~* 3 dry tubes with gel for serology, serum neutralisation test and serum library~* 1 cell preparation tube for the separation of immune cells within the circulating blood will be collected.
Study: NCT01251068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVOS 5100
Description: NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: near infrared spectroscopy device
Description: NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
Study: NCT03118063

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of pain by algometry
Description: Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of pain by algometry
Description: Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
Study: NCT04408001

Intervention type: BIOLOGICAL
Intervention: Saliva collection
Description: At each study visit, a saliva sample will be collected for the determination of IgA antibodies.

Intervention type: BIOLOGICAL
Intervention: Saliva collection
Description: At each study visit, a saliva sample will be collected for the determination of IgA antibodies.
Study: NCT00799071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: posaconazole (PSZ)
Description: Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
Study: NCT04477850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days
Study: NCT03789643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251
Description: Active drug tablets containing JTT-251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251
Description: Active drug tablets containing JTT-251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251
Description: Active drug tablets containing JTT-251

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching in appearance to the active drug tablets
Study: NCT02555007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study: NCT04447781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4800
Description: - Manufacturer: Inovio Pharmaceuticals Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4800
Description: - Manufacturer: Inovio Pharmaceuticals Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4800
Description: - Manufacturer: Inovio Pharmaceuticals Inc.
Study: NCT03118063

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of pain by algometry
Description: Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
Study: NCT02042599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedation with sevoflurane during 48-hr in ICU